Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

Oncologist

Volumn 13, Issue 5, 2008, Pages 503-514

  Brufsky, Adam ^a   Bundred, Nigel ^b   Coleman, Robert ^c   Lambert Falls, Rosemary ^d   Mena, Raul ^e   Hadji, Peyman ^f   Jin, Lixian ^g   Schenk, Nora ^g   Ericson, Solveig ^g   Perez, Edith A ^h  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d South Carolina Oncology Associates   (United States)

^e East Valley Hematology and Oncology Medical Group   (United States)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

^g NOVARTIS PHARMA AG   (Switzerland)

^h MAYO CLINIC   (United States)

Author keywords

Aromatase inhibitor; Breast neoplasm; Osteoporosis; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCIUM; LETROZOLE; MULTIVITAMIN; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE NECROSIS; BONE PAIN; BONE TURNOVER; BRAIN HEMORRHAGE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FRACTURE; HEADACHE; HOT FLUSH; HUMAN; HYGROMA; INSOMNIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; MYALGIA; NAUSEA; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; SUDDEN DEATH; SUICIDE;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; LUMBAR VERTEBRAE; MIDDLE AGED; NITRILES; OSTEOPOROSIS, POSTMENOPAUSAL; TRIAZOLES;

EID: 45749089797     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0206     Document Type: Article

References (34)

1. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486-492.
2. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
3. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007;369: 559-570.
4. Howell A, Cuzick J, Baum M et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365: 60-62.
5. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33(suppl 7):S13-S17.
6. Gnant M. Management of bone loss induced by aromatase inhibitors. Cancer Invest 2006;24:328-330.
7. Eastell R, Hannon RA, Cuzick J et al.; ATAC Trialists' Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-1223.
8. Lester J, Dodwell D, McCloskey E et al. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005;31: 115-142.
9. McCaig FM, Renshaw L, Williams L et al. A randomised study of the effects of letrozole and anastrozole on bone turnover. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
10. Geisler J, Lønning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. Eur J Cancer 2006;42:2968-2975.
11. Lønning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-5137.
12. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-836.
13. Liberman UA, Weiss SR, Bröll J et al.; Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
14. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early stage breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007;8:119-127.
15. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20:1029-1039; discussion 1039-1040, 1042, 1048.
16. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-828.
17. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.
18. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008;112:1001-1010.
19. De Boer R, Eidtmann H, Lluch A et al. The ZO-FAST trial: Zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
20. Brufsky A, Lund K, Cobb P et al. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006.
21. Brufsky A, Bosserman L, Caradonna R et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: The Z-FAST study 36-month follow-up. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
22. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA 2002;288:1889-1897.
23. National Cancer Institute. CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at http://ctep.info.nih.gov/reporting/ctc.html. Accessed October 11, 2007.
24. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261.
25. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936.
26. Buzdar AU. The ATAC (Arimidex®, Tamoxifen, Alone or in Combination) trial: An update. Clin Breast Cancer 2004;5(suppl 1):S6-S12.
27. Ruggiero S, Gralow J, Marx RE et al. Practical guidelines for the prevention, diagnosis, and treatment of osteoporosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
28. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
29. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 2008;26:1051-1057.
30. Hadji P, Appro M, Brufsky A et al. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007.
31. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301.
32. Recker RR, Delmas PD, Halse J et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008;23:6-16.
33. McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-128.
34. Hornby SB, Evans GP, Hornby SL et al. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 2003;72:519-527.